Moxifloxacin

Generic Name: Moxifloxacin

Brand Names: Avelox, Moxeza, Vigamox

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₄FN_₃O_₄

CAS Number: 151096-09-2

Unique Ingredient Identifier: U188XYD42P

Background: Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Indication: For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Associated Conditions: Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections

Associated Therapies: -

Clinical Trials

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

Phase 2

Terminated

Conditions: Community-Acquired Bacterial Pneumonia (CABP)

Interventions: Drug: JNJ-32729463
Drug: JNJ-32729463 (Open-Label)
Drug: moxifloxacin

First Posted Date: 2010-09-10

Last Posted Date: 2011-12-08

Lead Sponsor: Furiex Pharmaceuticals, Inc

Target Recruit Count: 32

Registration Number: NCT01198626

Locations: 🇵🇱
Furiex Research Site, Warszawa, Poland

Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773 (low)
Drug: BI 10773 Placebo
Drug: Moxifloxacin
Drug: BI 10773 (high)

First Posted Date: 2010-09-06

Last Posted Date: 2014-07-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT01195675

Locations: 🇩🇪
1245.16.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MAP0004
Drug: Inhaler Placebo
Drug: Moxifloxacin
Drug: Placebo Capsule

First Posted Date: 2010-08-31

Last Posted Date: 2014-01-09

Lead Sponsor: Allergan

Target Recruit Count: 54

Registration Number: NCT01191723

Locations: 🇺🇸
Cetero Research, Fargo, North Dakota, United States

A Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: moxifloxacin
Drug: GDC-0449
Drug: placebo

First Posted Date: 2010-08-02

Last Posted Date: 2017-02-17

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 61

Registration Number: NCT01173536

Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study

Phase 2

Completed

Conditions: Meningitis, Tuberculous
Pharmacokinetics
Pharmacodynamics
Tolerability

Interventions: Drug: Moxifloxacin

First Posted Date: 2010-07-08

Last Posted Date: 2012-06-07

Lead Sponsor: Universitas Padjadjaran

Target Recruit Count: 60

Registration Number: NCT01158755

Locations: 🇮🇩
Hasan Sadikin General Hospital, Bandung, West Java, Indonesia

Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-00232798
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2010-06-09

Last Posted Date: 2010-12-23

Lead Sponsor: Pfizer

Target Recruit Count: 44

Registration Number: NCT01140425

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

Phase 1

Completed

Conditions: Drug Toxicity

Interventions: Drug: HPN-100
Drug: Placebo
Drug: HPN-100 or Placebo
Drug: Moxifloxacin

First Posted Date: 2010-06-03

Last Posted Date: 2024-06-20

Lead Sponsor: Amgen

Target Recruit Count: 98

Registration Number: NCT01135680

Locations: 🇺🇸
Covance Clinical Pharmacology, Inc., Madison, Wisconsin, United States

A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers

Phase 1

Completed

Conditions: Pulmonary Disease
Lung Disease
Moxifloxacin

Interventions: Drug: moxifloxacin
Drug: placebo
Drug: PF-00610355

First Posted Date: 2010-04-20

Last Posted Date: 2011-01-13

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT01107054

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Antibiotic or Not in Non-purulent Exacerbations of COPD: a Trial of Security and Efficacy

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Moxifloxacin

First Posted Date: 2010-03-24

Last Posted Date: 2018-07-06

Lead Sponsor: Fundacion Clinic per a la Recerca Biomédica

Target Recruit Count: 73

Registration Number: NCT01091493

Locations: 🇪🇸
Fundacio Clinic Per la Recerca Biomèdica - Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain
🇪🇸
Fundació La Fe- Hospital La Fe, Valencia, Comunitat Valenciana, Spain
🇪🇸
Hospital Miquel Servet, Zaragoza, Aragon, Spain

and more 1 locations

A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.

Phase 1

Withdrawn

Conditions: Infections, Bacterial

Interventions: Drug: GSK945237
Drug: Placebo
Drug: Linezolid
Drug: Moxifloxacin

First Posted Date: 2009-12-25

Last Posted Date: 2015-04-22

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT01039610

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy